New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial скачать в хорошем качестве

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

The results of the NIAGARA trial have yielded a new standard of care for patients with muscle-invasive bladder cancer (MIBC), according to Michael Serzan, MD, Dana-Farber Cancer Institute, Boston, Massachusetts. Dr. Serzan highlighted some of the new questions that have emerged after the trial regarding perioperative durvalumab while speaking with Albert Jang, MD, University Hospitals of Cleveland, Cleveland, Ohio, at the 2025 American Society of Clinical Oncology Annual Meeting. For example, the potential role of circulating tumor DNA (ctDNA) in guiding treatment intensity in the future. Dr. Serzan raised the question of whether all patients require continued adjuvant durvalumab, or if treatment could be deescalated based on ctDNA clearance and other pathological markers. Regardless of ctDNA status, Dr. Serzan continues to treat patients with adjuvant durvalumab based on the NIAGARA data, although his decision depends on each patient’s surgical recovery and treatment tolerance. In addition, he stressed that treatment goals differ between patients who are treated with curative intent versus patients with metastatic disease, both of which are factors that can often shape treatment discussion. Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ •⁠ Main Channel:    / @oncologybrothers